The stock of Neogenomics Inc. (NEO) has seen a 3.64% increase in the past week, with a -1.30% drop in the past month, and a -13.17% decrease in the past quarter. The volatility ratio for the week is 2.28%, and the volatility levels for the past 30 days are at 3.17% for NEO. The simple moving average for the past 20 days is 2.47% for NEO’s stock, with a -9.94% simple moving average for the past 200 days.
Is It Worth Investing in Neogenomics Inc. (NASDAQ: NEO) Right Now?
NEO has 36-month beta value of 1.17. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NEO is 126.12M, and currently, short sellers hold a 4.82% ratio of that float. The average trading volume of NEO on June 28, 2024 was 728.61K shares.
NEO) stock’s latest price update
Neogenomics Inc. (NASDAQ: NEO) has seen a rise in its stock price by 2.32 in relation to its previous close of 13.34. However, the company has experienced a 3.64% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-06-13 that FORT MYERS, Fla.–(BUSINESS WIRE)–Fort Myers’ Mayor, Kevin Anderson, will be proclaiming June as NeoGenomics’ Commitment to Cancer Month.
Analysts’ Opinion of NEO
Many brokerage firms have already submitted their reports for NEO stocks, with Craig Hallum repeating the rating for NEO by listing it as a “Buy.” The predicted price for NEO in the upcoming period, according to Craig Hallum is $26 based on the research report published on May 01, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NEO reach a price target of $21, previously predicting the price at $25. The rating they have provided for NEO stocks is “Buy” according to the report published on December 29th, 2023.
Stephens gave a rating of “Overweight” to NEO, setting the target price at $18 in the report published on August 21st of the previous year.
NEO Trading at -3.02% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.67% of loss for the given period.
Volatility was left at 3.17%, however, over the last 30 days, the volatility rate increased by 2.28%, as shares sank -2.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, NEO rose by +3.87%, which changed the moving average for the period of 200-days by +0.07% in comparison to the 20-day moving average, which settled at $13.31. In addition, Neogenomics Inc. saw -15.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NEO starting from Olivo Alicia C, who sale 1,049 shares at the price of $15.74 back on May 15 ’24. After this action, Olivo Alicia C now owns 44,867 shares of Neogenomics Inc., valued at $16,511 using the latest closing price.
TETRAULT LYNN A., the Director of Neogenomics Inc., sale 6,112 shares at $15.97 during a trade that took place back on Mar 04 ’24, which means that TETRAULT LYNN A. is holding 50,062 shares at $97,579 based on the most recent closing price.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Neogenomics Inc. stands at -0.14. The total capital return value is set at -0.06. Equity return is now at value -8.88, with -5.03 for asset returns.
Based on Neogenomics Inc. (NEO), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at 0.59. The interest coverage ratio of the stock is 50.47.
Currently, EBITDA for the company is -6.52 million with net debt to EBITDA at -32.32. When we switch over and look at the enterprise to sales, we see a ratio of 3.31. The receivables turnover for the company is 4.3for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
To put it simply, Neogenomics Inc. (NEO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
